Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by kickstartmyharton Mar 24, 2020 11:42am

113 Views

Post# 30841821

RE:Yes, it looks like some $$$ are leaving AGN for the others,

I asked Equity Insight this question and here's their response re: the interview:

Q: On March 13th Algernon contacted the Gates Foundation regarding funding for the development of new COVID-19 treatments. What was the result of this contact, are there any updates and will the foundation be providing funding?

A: Your question has been added to our list and we anticipate that the interview will be completed and published later this week!

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages